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Chapter 8
Summary, conclusions and general discussion
Documentation of the natural history of childhood asthma is necessary for understanding
the disease, for counseling parents and children with asthma and assessing treatment.
Studies on the natural history of asthma are limited. Most studies on asthma have been
either cross-sectional in nature, or have followed a cohort of asthmatics for a relatively
short duration. In studies that start at an adult age, it is difficult to separate subjects with
asthma from those with chronic obstructive pulmonary disease (COPD) Therefore, the
results of these studies could be a constitute of mixed messages resulting from subjects
with asthma and COPD There is another reason why studies which start in childhood
may give different results than studies which start in adulthood. Studies on childhood
asthma have shown that about 50 % of the children with asthma outgrow their disease
during puberty as assessed by symptoms (l-3). Thus. only a part of the population of
children with asthrna are seen by an adult lung specialist. This could imply that the
population with asthma seen by a pediatrician is phenotypically different from the adult
asthmatic population.
The subject of this thesis is a long-term follow-up study over 30 years, starting in
childhood. lnitially, and during repeated follow-up visits, we performed objective
measurements and asked questions about several important issues like medication use.
We investigated which factors at the start of the study were associated with the outcome
of asthma One of the characteristics of asthma is an increased bronchial responsiveness
to a variety of inhaled stimuli, like cigarette smoke and cold air. This increased
responsiveness can be objectivated by measuring the responsiveness of the airways to
e.g histamine, methacholine or adenosine 5'- monophosphate. Primary outcome
parameters of our study were bronchial responsiveness as measured by PCls histamine.
lung function as measured by FEVI and the presence or absence of current symptoms.
Recent studies have shown that subjects with bronchial hyperresponsiveness and
subjects with asthrna have a greater decline in lung function than those without bronchial
hyper-responsiveness and asthma (4-7), suggesting that every effort should be made to
reduce bronchial hyperresponsiveness and to prevent asthma or to give an optimal
treatment intervention. There is also evidence that subjects with asthma have an
increased risk of mortality, compared to subjects without asthma (7,8).
All consensus reports focus on the knowledge that inflammatory processes underlie the
clinical expression of asthma, and advocate anti-inflammatory treatment like inhaled
corticosteroids as the first line therapy when symptoms occur at least once a week
Inhaled corticosteroids have beneficial effects not only in terms of symptoms, but also in
terms of lung function, bronchial responsiveness, diurnal peak expiratory flow (PEF)
variabilitv and long-term outconre of asthma (9-12) Despite the high prevalence of
asthma and the knowledge about its pathophysiology. the optimal treatment strategy for
the individual asthmatic subject is not yet known. With the introduction of long-acting









































Summarl. conclusiuns ontt general discusston
available. We evaluated the effect and safety of a new inhaled corticosteroid, fluticasone
propionate on several outcome parameters of asthma in children. In a long-term study
we evaluated the role of salmeterol, a new long-acting B2 agonist, in the treatment of
children with mild to moderately severe asthma.
In Chapter I a general introduction, the background and the aims of the studies are
given. The lack of a clear definition of asthma has impeded studies on this disease. Many
attempts have been made to develop a definition of asthma useful both in the clinical
setting and in population studies. This lack of definition makes it difficult to study the
prognosis of asthma from childhood to adulthood.
To investigate which factors may be associated with the progression or remission of
asthma, a review of published studies on the outcome of asthma, is given in Chapter 2.
The effect of age at onset of symptoms, severity of symptoms, allergy, bronchial
responsiveness, lung function, viral infections, eczema, gender, active and passive
smoking and therapy on the long-term outcome of asthma are being discussed.
From the factors mentioned above, bronchial responsiveness i  an important risk factor
for both the development and outcome of asthma (13-19). Asthma is a chronic
inflammatory process of the airways, and bronchial responsiveness is thought to
indirectly reflect this inflammatory process. Bronchial responsiveness has been
associated with an increase in symptomatology and need for asthma medication, and a
lower pulmonary function. Therefore, we investigated in Chapter 3 which childhood
and early adulthood risk factors are associated with the persistence of bronchial
responsiveness into adulthood, and which childhood factors are related to either
improvement or worsening in bronchial responsiveness from childhood to adulthood.
We also wanted to determine which cross-sectional factors are associated with the
severity of bronchial responsiveness at age 32-42 year .
In a 30-year follow-up study, I l9 allergic asthmatic subjects were measured 3 times, at
age 5-14 yr (visit 1),22-32 yr (visit 2) and 32-42 yr (visit 3). Different lung function
tests, blood tests and allergv tests were measured, a questionnaire was used and physical
examination was performed. A better lung function, assessed by FEVl in childhood was
associated with less severe bronchial responsiveness at age 32-42, independent of other
potential risk factors. Larger increases in lung function (FEV1 values) both from
childhood to early adulthood and from early adulthood to age 32-42, a longer time
interval from the first to the third measurement and having pets in childhood were
associated with less severe bronchial responsiveness at age 32-42. 'fhe same factors
were found to be associated with less deterioration of bronchial responsiveness fi'om
visit 2 to 3. In our study we found an increase in bronchial responsiveness over time in
both smokers and ex-smokers. Because smokers have a higher level of lgE (20,21), we
separately analyzed the effect of IgE in non-smokers, ex-smokers and smokers. In non-
smokers, a higher IgE level at visit 2 (22-32 yr) was a risk factor for more severe
bronchial responsivene ss at age 32-42.
When we determined cross-sectionally which factors at age 32-42 yr were associated
with the severity of bronchial responsiveness at that age, a low level of lung function and
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Chapter I
presence of asthma symptoms were associated with more severe bronchial
responsiveness. while older age and having pets were associated with less severe
bronchial responsiveness. lgE was related to more severe bronchial responsiveness only
in non-smokers.
We conclude that a lower lung function in childhood, and less improvement in lung
function over time and a high level of IgE in non-smokers were associated with more
severe bronchial responsiveness in adulthood.
Another important factor associated with the outcome of asthma is lung function as
assessed by FEV1. Symptom severity, like wheezing and dyspnea are related to
pulmonary function (25,26). It is therefore important to know which factors in early
adulthood are associated with the level of FEVr and which factors are associated with
an accelerated decline in FEVr throughout adulthood. In Chapter 4 risk factors for
growth and decline of lung function over a period of 3O-year were assessed in the same
group of asthmatics as'mentioned in Chapter 3. A low level of lung function and more
severe hyperresponsiveness in childhood were shown to be independent risk factors for
a low level of FEVI in early adulthood ar age22-32 year. A smaller FEVI decline after
age 22-32 occurred in those asthmatics who stopped smoking and who continued to use
inhaled corticosteroids. Our data stress the importance to study intervention strategies in
young childhood and early adulthood to prevent or to postpone further lung function
deficit.
Asthma is a very common disease, for which there is still no cure lt is important to
know which factors contribute to the best attainable outcome of the disease. In Chapter
5 we investigated which factors in childhood and early adulthood are associated with
remission of asthma over a period of 3O-year. In our study we defined remission of
asthma as the absence of bronchial hyperresponsiveness, having a good lung function,
expressed as FEV; >90oÁ predicted, absence of wheeze and asthma attacks and no need
for inhaled corticosteroids. We also investigated which co-variables are associated with
the separate components that constitute our definition of remission of asthma. We found
that 22oÁ of our study group had asthma remission at age 32-42 A better lung function
early in life and a higher increase in lung function from age 5-14 to 22-32 were
significantly associated with this remission of asthma. Being female was borderline
significantly associated with absence of asthma at age 32-42 Almost 50 % of the
group of subjects who did still have asthma at age 32-42 did not report symptoms of
wheeze and/or asthma attacks, while they still had bronchial hyperresponsiveness, or a
low lung function, or used inhaled corticosteroids or had a combination of these three.
If we diagnosed remission of asthma oniy on the absence of symptoms, we would get a
higher percentage of asthma remission, ll oÁ instead of 22 % Using absence of
symptoms as definition for outgrowing asthma will miss subjects with ongoing airway
inflammation based on objective measurements,
For the separate components, we found that a higher level of lung function at visit I was
significantly associated with a good lung function at age 32-42 yr , and with no need for
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Summary, conclusions and general discussion
inhaled corticosteroids at age 32-42. A, higher increase in lung function from age 5-14 to
age 32-42 was significantly associated with absence of symptoms at age 32-42 yr , and
with a good lung function at age 32-42 yr The absence of hyperresponsiveness at visit
2, and a low level of serum total IgE at visit 2 are significantly associated with the
absence of hyperresponsiveness aL age 32-42. We concluded that the outcome of asthma
is strongly related to its definition, i.e. different results are shown when outcome of
asthma is defined as absence of symptoms or when it is defined as having a good lung
function or absence of bronchial hyperresponsiveness or a combination of these
components. Only a part of symptomatic asthmatic children will outgrow their disease,
as assessed by objective measurements at age 32-42, and that a better lung function
early in life and a higher increase in lung function from age 5-14 to 22-32 is associated
with this absence of asthma.
Despite the high prevalence of asthma and the recent knowledge about its
pathophysiology, the optimal treatment strategy for asthma is yet unknown, especially
with regard to the long-term outcome of the disease. The first choice in asthma
management is anti-inflammatory medication, such as inhaled corticosteroids, combined
with on demand short-acting B2-agonists for symptom relief. With the introduction of
more potent inhaled corticosteroids and long-acting B2-agonists, new therapeutic
strategies became available. In Chapter 6 we have described effects and side-effects of
treatment with a recently developed inhaled corticosteroid, fluticasone propionate, in 34
children with stable moderately severe asthma, in a double blind placebo-controlled trial
After a run-in period of 2 weeks and a treatment period of 3 months there was a follow-
up period of 4 weeks during which only bronchodilators were allowed. At home,
symptoms of asthma, the use of B2-agonists and peak expiratory flow (PEF) values were
noted in a diary two times a day. Lung function, bronchial hyperresponsiveness (PCto-
histamine) and reversibility to B2-agonists were determined each month We found that
wheezing improved and all PEF values increased during treatment with fluticasone
propionate. Lung function as assessed by FEVI and bronchial responsiveness improved,
and reversibility with 800 pg salbutamol decreased in the fluticasone propionate group
All observed changes were significant, with exception of the change in nocturnal PEF.
The effect of fluticasone propionate on symptoms and lung function were transient.
since all parameters had returned to pre-treatment values four weeks after cessation of
fluticasone propionate. Side effects of fluticasone propionate on the hypothalamus-
pituitary-adrenal axis (FIPA-axis) were measured by serum and urinary cortisol
concentration under fasting conditions. The serum cortisol level did not change during
treatment, he urinary cortisol level significantly decreased in the fluticasone propionate
group. The latter was, however, only significant when the decrease was compared with
an unexplained increase in the placebo group. We conclude that fluticasone propionate
100 prg b.i.d. is effective in children with moderately severe, stable asthma With respect
to side effects, additional studies are necessary to exclude suppression ofthe FIPA-axis
during treatment with fluticasone propionate 100 pg b.i d
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Studies in adults have shown that addition of salmeterol to a moderate dose of inhaled
corticosteroid results in a better symptom control and higher PEF values, compared
with a doubling dose of the inhaled corticosteroid (27,28). The place of this long-acting
B2-agonists in the treatment of asthma in children is not known and should be further
elucidated. In Chapter 7 we describe the results of a multicenter study in which the
addition of salmeterol (50 pg b.i.d ) to a moderate dose of an inhaled corticosteroid
(beclomethasone 200 pg b.i.d.) was compared to doubling the dose of an inhaled steroid
(beclomethasone 400 pg b.i.d.) and to the initial inhaled corticosteroid (beclomethasone
200 pg dose) In a double-blind placebo controlled parallel study, 177 children with mild
to moderately severe asthma participated. After one year of treatment no significant
differences between the three trealment groups were found for pre- and post-
bronchodilator lung function as assessed by FEVI and bronchial responsiveness as
assessed by PD2s methacholine. However, significant improvements from baseline
values were found for FEV1 and PD2e methacholine in all three groups. For morning
and evening peak flow values, there was a slight advantage in the group who used
salmeterol and inhaled corticosteroids in a moderate dose compared to the group which
used inhaled corticosteroids at a moderate dose only, especially during the first months
of the treatment period No significant differences were found between groups for
symptom scores, use of additional salbutamol and exacerbation rates (13 courses of
prednisolone to l0 patients in the beclomethasone 400 Fg +salmeterol group, 8 courses
to 7 patients in the beclomethasone 800 prg, and 13 courses to 10 patients in the
beclomethasone 400 pg treated group) Growth was significantly more retarded in the
group which used a double dose of inhaled corticosteroids. Compliance was high in all
treatment groups, where nearly 90oÁ of prescribed medication was used. We conclude
that adding salmeterol or doubling the dose of beclomethasone had no additional benefit
to 200 pg beclometasone b.i.d. in this selected group of children with moderately severe
asthma, in which the compliance with medication was excellent.
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